IBSA Pharma
ActiveThe computed 12-month bankruptcy probability of IBSA Pharma is 2.9% (moderate). The 2025 annual accounts show equity of €35k and a net result of €1k. Equity is growing by ~11% per year across the filed fiscal years. Its solvency ranks better than 54% of 4844 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
56
/ 100
Fair
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability42▼-12
Solvency74▲+12
Growth52▼-26
Track record94
Bankruptcy probability, 12 months
2.9%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €1.5k at 30 days acceptable
Liquidity ample (current ratio 1.95 against 1.59 in 2024; short-term debt: 51.4% and cash: 28.7% of total assets), but 51.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
48.6%
Return on assets
1.8%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-05-2026, 73 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
73 d early
2024
84 d early
2023
2 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€1k▼ 78.8%
2024 · €6k
2023: €2k
2024: €6k
2023 → 2025
Working capital
€35k▲ 3.9%
2024 · €34k
2023: €27k
2024: €34k
2023 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line202320242025Trend
Equity€27k-€34k▲ 22.3%€35k▲ 3.9%
Operating result€8k-€21k▲ 150%€19k▼ 10.7%
Net result€2k-€6k▲ 151%€1k▼ 78.8%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 11% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €72k
Equity
€35k▲ 3.9%
Debt
€37k▼ 35.6%
The debt ratio falls from 63.0% to 51.4%. Equity is higher and debt is lower.
Key figures and ratios
Solvency
48.6%▲
2024 · 37.0%
Current ratio
1.95▲
2024 · 1.59
Quick ratio
1.95▲
2024 · 1.59
Debt / equity
1.06▼
2024 · 1.71
ROE
3.7%▼
2024 · 18.2%
ROA
1.8%▼
2024 · 6.7%
Debt
€37k▼
2024 · €57k
Debt ≤ 1 year
€37k▼
2024 · €57k
Income taxes
€11k▲
2024 · €8k
Staff costs
€233k▼
2024 · €297k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€91k€72k▼
Current assets29/58€91k€72k▼
Amounts receivable within one year40/41€57k€50k▼
Trade receivables40€44k€48k▲
Other amounts receivable41€13k€2k▼
Cash at bank and in hand54/58€32k€21k▼
Deferred charges and accrued income490/1€2k€2k▼
Equity and liabilities
Total equity and liabilities10/49€91k€72k▼
Equity10/15€34k€35k▲
Contributions10/11€25k€25k=
Profit (loss) carried forward14€9k€10k▲
Amounts payable17/49€57k€37k▼
Amounts payable within one year42/48€57k€37k▼
Trade debts44€10k€6k▼
Suppliers440/4€10k€6k▼
Taxes, remuneration and social security45€47k€30k▼
Taxes450/3€25k€16k▼
Remuneration and social security454/9€23k€15k▼
Income statement
Code20242025
Remuneration, social security and pensions62€297k€233k▼
Other operating charges640/8-€465
Gross operating margin9900€318k€253k▼
Operating profit (loss)9901€21k€19k▼
Financial income75/76B€1€0▼
Recurring financial income75€1€0▼
Financial charges65/66B€7k€7k▼
Recurring financial charges65€7k€7k▼
Profit (loss) for the period before taxes9903€14k€12k▼
Income taxes67/77€8k€11k▲
Profit (loss) for the period9904€6k€1k▼
Profit (loss) for the period to be appropriated9905€6k€1k▼
Appropriation of the result
Profit (loss) to be appropriated9906€9k€10k▲
Profit (loss) brought forward from the previous period14P€2k€9k▲
Social balance
Average headcount (FTE)90872.02.0=
The notes to these accounts (3 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
19-05
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Weakest financial yearnet €1k ▼78.8%
Net result drops to €1k, the lowest in the series.
08-05
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Highest result since 2023net €6k ▲151%
Operating result €21k, net result €6k, both a record.
29-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brussel · 1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
de Meeûssquare 371000 BrusselGround area
1,035 m²
Building footprint
895 m²
Volume, LiDAR
16,030 m³
Parcel 21805E0463/00W002, Brussels · tallest building 32.6 m, ±8 floors. Linked by address, not a title deed.
1 establishment unit
IBSA Pharma
since 20222.341.865.951
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21805E0463/00W002 | Brussels | 1,034 m² | 1 · 895 m² | 32.6 m · 8 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
CIRBA
BE 0877.341.838
Elsene · Eq €35k
DM GS
BE 0819.098.088
Erquelinnes · Eq €35k
Key for Management and Translation
BE 0545.744.368
Sint-Pieters-Leeuw · Eq €34k
DENTAL BUDGET
BE 0791.483.277
Gent · Eq €34k
BELIPHARM
BE 0884.446.592
Leuven · Eq €36k
Of 1,898 companies in sector 46460 we hold annual accounts for 1,116. 412 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded22-12-2022
Fiscal year end31-12
Activities, NACEBEL
46460Wholesale of pharmaceutical and medical goods
46150Agents in the wholesale of furniture, household goods and hardware
Sources
Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.